Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia

详细信息    查看全文

• 作者：Satoaki Matoba ; Tetsuya Tatsumi ; Toyoaki Murohara ; Tsutomu Imaizumi ; Yousuke Katsuda ; Masaaki Ito ; Yoshihiko Saito ; Shiro Uemura ; Hiroshi Suzuki ; Shinya Fukumoto ; Yasutaka Yamamoto ; Rie Onodera ; Satoshi Teramukai ; Masanori Fukushima ; Hiroaki Matsubara ; TACT Follow-up Study Investigators
• 刊名：American Heart Journal
• 出版年：2008
• 出版时间：November 2008
• 年：2008
• 卷：156
• 期：5
• 页码：1010-1018
• 全文大小：343 K

文摘

Background

Angiogenic cell therapy by intramuscular injection of autologous bone marrow mononuclear cells was first attempted in patients with peripheral artery disease (PAD) with critical limb ischemia, and the feasibility was shown by a randomized controlled Therapeutic Angiogenesis by Cell Transplantation (TACT) study.

Methods and Results

The present study was designed to assess the 3-year safety and clinical outcomes of this angiogenic cell therapy by investigating the mortality and leg amputation-free interval as primary end points. The median follow-up time for surviving patients was 25.3 months (range, 0.8-69.0 months), and 3-year overall survival rates were 80 % (95 % CI 68-91) in patients with atherosclerotic peripheral arterial disease (11 died in 74 patients) and 100 % (no death) in 41 patients with thromboangiitis obliterans (TAO; Buerger's disease). Three-year amputation-free rate was 60 % (95 % CI 46-74) in PAD and 91 % (95 % CI 82-100) in patients with TAO. The multivariate analysis revealed that the severity of rest pain and repeated experience of bypass surgery were the prognostic factors negatively affecting amputation-free interval. The significant improvement in the leg pain scale, ulcer size, and pain-free walking distance was maintained during at least 2 years after the therapy, although the ankle brachial index and transcutaneous oxygen pressure value did not significantly change.

Conclusions

The angiogenic cell therapy using bone marrow mononuclear cells can induce a long-term improvement in limb ischemia, leading to extension of amputation-free interval. The safety and efficacy are not inferior to the conventional revascularization therapies.